Literature DB >> 2693112

Evaluation of fever in the patient with cancer.

P A Pizzo1.   

Abstract

During the last decade, the survival of patients with fever and neutropenia has continued to improve. This is largely a reflection of the increasing repertoire of antimicrobial agents available to treat the fevers and infections that arise in this ever-increasing population of patients. Although it would be optimal if therapeutic decisions could always be made based on the microbial isolates and their sensitivity patterns, this is generally not possible in the cancer patient. Fever remains the predominant manifestation of infection, but the underlying microbial etiology is infrequently delineated. In spite of improved diagnostic tests, clinical acumen along with vigilant and repetitive patient assessment remain the cornerstone for evaluation of the cancer patient who becomes febrile. Indeed, strict adherence to simple principles can have a significant impact on improving the chances for survival of cancer patients who develop fever or infection.

Entities:  

Mesh:

Year:  1989        PMID: 2693112

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  6 in total

1.  Validity of earlier positivity of central venous blood cultures in comparison with peripheral blood cultures for diagnosing catheter-related bacteremia in cancer patients.

Authors:  V B Malgrange; M C Escande; S Theobald
Journal:  J Clin Microbiol       Date:  2001-01       Impact factor: 5.948

Review 2.  Biomarkers for the differentiation of sepsis and SIRS: the need for the standardisation of diagnostic studies.

Authors:  T C Hall; D K Bilku; D Al-Leswas; C Horst; A R Dennison
Journal:  Ir J Med Sci       Date:  2011-07-30       Impact factor: 1.568

3.  Detection of bacteraemia in patients with fever and neutropenia using 16S rRNA gene amplification by polymerase chain reaction.

Authors:  B E Ley; C J Linton; D M Bennett; H Jalal; A B Foot; M R Millar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

4.  Cost effectiveness of cephalosporin monotherapy and aminoglycoside/ureidopenicillin combination therapy. For the treatment of febrile episodes in neutropenic patients.

Authors:  J A Paladino; L D Fong; A Forrest; R Ramphal
Journal:  Pharmacoeconomics       Date:  2000-10       Impact factor: 4.981

5.  Value of measurement of C-reactive protein in febrile patients with hematological malignancies.

Authors:  E Rintala; K Irjala; J Nikoskelainen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-11       Impact factor: 3.267

6.  Procalcitonin as a biomarker of bacterial infection in sickle cell vaso-occlusive crisis.

Authors:  Dilip Kumar Patel; Manoj Kumar Mohapatra; Ancil George Thomas; Siris Patel; Prasanta Purohit
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-02-17       Impact factor: 2.576

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.